| Literature DB >> 30586852 |
Rajan Sharma Bhattarai1, Rinda Devi Bachu2, Sai H S Boddu3, Sarit Bhaduri4,5.
Abstract
The electrospinning process has gained popularity due to its ease of use, simplicity and diverse applications. The properties of electrospun fibers can be controlled by modifying either process variables (e.g., applied voltage, solution flow rate, and distance between charged capillary and collector) or polymeric solution properties (e.g., concentration, molecular weight, viscosity, surface tension, solvent volatility, conductivity, and surface charge density). However, many variables affecting electrospinning are interdependent. An optimized electrospinning process is one in which these parameters remain constant and continuously produce nanofibers consistent in physicochemical properties. In addition, nozzle configurations, such as single nozzle, coaxial, multi-jet electrospinning, have an impact on the fiber characteristics. The polymeric solution could be aqueous, a polymeric melt or an emulsion, which in turn leads to different types of nanofiber formation. Nanofiber properties can also be modified by polarity inversion and by varying the collector design. The active moiety is incorporated into polymeric fibers by blending, surface modification or emulsion formation. The nanofibers can be further modified to deliver multiple drugs, and multilayer polymer coating allows sustained release of the incorporated active moiety. Electrospun nanofibers prepared from polymers are used to deliver antibiotic and anticancer agents, DNA, RNA, proteins and growth factors. This review provides a compilation of studies involving the use of electrospun fibers in biomedical applications with emphasis on nanoparticle-impregnated nanofibers.Entities:
Keywords: applications; drug delivery; electrospinning; parameters
Year: 2018 PMID: 30586852 PMCID: PMC6358861 DOI: 10.3390/pharmaceutics11010005
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Schematic of electrospinning system. The system consists of polymer solution/melt in a syringe, mounted on a syringe pump, operating at a constant slow speed. High voltage direct current supply is connected to the needle of the syringe to charge the fluid. With sufficient voltage, the fluid forms a Taylor cone and then jet erupts from the cone towards the collector plate with whipping instability.
Figure 2The effect of applied electric field on Taylor cone formation (dark colored tip). At low electric field, pendant drop is formed at the tip of the capillary and then a cone is formed on the tip. When the applied voltage is increased gradually, the drop size decreases until just a cone is formed at the tip of the capillary. If the voltage is further increased, fiber formation starts from within the needle without forming a visible Taylor cone on the blunt tip of the needle.
Figure 3Side-by-side electrospinning schematic diagram: Polymer solutions 1 and 2 pass through separate capillaries, which are connected to the same high voltage supply, at either the same or different rates. A single Taylor cone is formed, which ejects the jet with non-uniform mixture of both the polymer solutions and, after drying, is deposited on the collector.
Figure 4Coaxial electrospinning schematic diagram: Polymer solution 2 is passed through the inner capillary tube, while polymer solution 1 is passed through the outer capillary tube. The Taylor cone is formed where the inner solution (polymer solution 2) is surrounded by the outer solution. The jet erupts from the Taylor cone, and during that process, the polymer in the inner layer is coated with the polymer in the outer layer. The dried fiber with a core-shell design is then deposited on the collector.
Figure 5Graphical presentation of multi-drug delivery system: (A) overview; (B) cross sectional view of a tetra-layered sequential electrospun mesh. Cross-sectional view consists of drug loaded mesh (layer I), barrier mesh (layer II), second drug loaded mesh (layer III) and basement mesh (layer IV). Redrawn from [102].
Studies involving the use of electrospun fibers in drug delivery (partial listing).
| Drug(s) | Polymer(s) | Solvent Composition | Spraying Type |
|---|---|---|---|
|
| |||
| Tetracycline hydrochloride | PEUU and PLGA [ | 1,1,1,3,3,3-Hexafluoro-2-propanol [ | Single nozzle; Coaxial [ |
| Gentamycin sulfate and Resveratrol (antioxidant) | PCL [ | Chloroform: ethanol (3:1) | Coaxial |
| Ciprofloxacin Hydrochloride | PVA, Poly(vinyl acetate) [ | Diluted acetic acid solution | Single nozzle |
| Fusidic acid and rifampicin | PLGA [ | Tetrahydro Furan/Dimethylformamide | Single nozzle |
| Mefoxin | PLGA [ | DMF | Single nozzle |
| Metronidazole benzoate | PCL [ | Dichloromethane (DCM:DMF) | Single nozzle |
| Ciprofloxacin hydrochloride, | coPLA, coPLA/PEG [ | DCM:DMSO (3:1) | Single nozzle |
| Lidocaine and mupirocin | PLLA [ | Hexafluoroisopropanol | Dual spinneret |
| Ornidazole (Biteral®) | PCL | Chloroform and DMF (3:7) | Single nozzle |
| Potassium 5-nitro-8-quinolinolate | Chitosan/PEO [ | 2% ( | Single nozzle |
| Itraconazole and ketanserin | PU [ | DMF, DMAc | Single nozzle |
| Pleurocidin | PVA [ | Distilled water | Single nozzle |
|
| |||
| Ketoprofen | PVA/PAA/MWCNT [ | Deionized water [ | Single nozzle |
| Ibuprofen | PLGA PEG-g-CHN [ | DMF | Side-by-side |
| Fenbufen | PLGA/Gelatin [ | 2,2,2-trifluoroethanol | Single nozzle |
| Rhodamine B/Naproxen | Chitosan nanoparticles/PCL composite [ | Acetic acid/chloroform: methanol (3:1) | Single nozzle yet core/sheath fiber |
| Meloxicam | PVA [ | Water | Single nozzle |
|
| |||
| Doxorubicin [ | PLLA [ | Chloroform-methano-DMSO [ | Single nozzle |
| Hydroxycamptothecin | HPCD [ | DMSO | Emulsion |
| Paclitaxel | Chitosan/PEO/HA [ | Acetic acid/distilled water [ | Single nozzle |
| Cisplatin | PLA/PLGA [ | DCM | Single nozzle |
| Dichloroacetate | PLA [ | Chloroform | Single nozzle |
| 1,3-Bis(2-chloroethyl)-1-nitrosourea | PEO and PEG-PLLA [ | Chloroform | Single nozzle/Emulsion |
| Curcumin | Cellulose acetate [ | Acetone/dimethylacetamide (2:1) | Single nozzle |
| Green tea polyphenols (GTP) | PCL/MWCNT [ | Dichloromethane | Single nozzle |
| Titanocene dichloride | PLLA [ | Dichloromethane | Single nozzle |
PLA: Poly(lactic acid); PEVA-Poly(ethylene-co-vinylacetate); PCL: poly(ε-caprolactone); PCL-co-PCLEEP: Copolymer of caprolactone and ethyl ethylene phosphate; PLGA: Poly(d,l-Lactic acid-co-glycolic acid); PEUU: poly(ester urethane) urea; EC: ethyl cellulose; PEO: Poly(ethylene oxide); PU: Polyurethane; DMAc: Dimethylacetamide; PETA: pentaerythritol triacrylate; PEI-HA: Poly(ethylenimine)-hyaluronic acid; PVP: polyvinylpyrrolidone; PEG-g-CHN: poly(ethylene glycol)-g-Chitosan; PEG-PLA: poly(ethylene glycol)-poly(lactic acid); PLLA: poly(l-lactic acid); HPCD: 2-hydroxypropyl-β-cyclodextrin; HA: Hyaluronic acid; MWCNT: multi-walled carbon nanotubes, PAA–Poly(acrylic acid); PECCL: poly(ethylene carbonate-ε-caprolactone); PDLLA: poly(d,l-lactic acid).
Studies involving the use of electrospun fibers in delivery of proteins, DNA, RNA and human factors (partial listing).
| Drug(s) | Polymer(s) | Solvent Composition | Spraying Type |
|---|---|---|---|
| plasmid DNA (pDNA) | PEI-HA [ | Coaxial | |
| siRNA | PCL [ | 2,2,2-Trifluoroethanol (TFE) [ | Single nozzle |
| Human glial cell-derived neurotrophic factor | PCL-co-PCLEEP [ | Dichloromethane | Single nozzle |
| Human β-nerve growth factor | PCL-co-PCLEEP [ | Dichloromethane | Single nozzle |
| Endothelial growth factor VEGF | PECCL [ | - | Single nozzle |
| Bovine Serum Albumin (BSA) | PEO [ | Deionized water | Single nozzle |
| Lysozyme | PLA [ | Chloroform | Emulsion |
| Human-nerve growth factor (NGF) | Poly(L-lactide-co-caprolactone) [ | Chloroform | Emulsion |
| DNA | PLA-PEG and PLGA [ | DMF | Single nozzle |
| Growth factors (VEGF, PDGF) | Poly(urethane) [ | Chloroform: ethanol (75:25) | Coaxial |
| Horseradish peroxidase | PVA/PCL [ | - | Coaxial |
Studies involving the use of electrospun fibers in tissue engineering (partial listing).
| Drug(s) | Polymer(s) | Solvent Composition | Spraying Type |
|---|---|---|---|
| Wound healing, tissue engineering, hemostatic agent | Collagen-PEO [ | Hydrochloric acid | Single nozzle |
| Adenovirus with gene for green fluorescent protein | Poly(ε-caprolactone) [ | Chloroform: ethanol (75:25) | Coaxial |
| Guided tissue regeneration | PDLLA/PLGA [ | Chloroform:DMF (9:1) and THF/DMF (3:1) | Single nozzle |